Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Aspirin
100%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
100%
Non-aspirin Non-steroidal Anti-inflammatory Drugs
100%
Progression-free Survival
28%
Overall Survival
28%
Metastatic RCC
21%
Drug Users
21%
Hazard Ratio
14%
Renal Cell Carcinoma
7%
Adverse Events
7%
Overall Response Rate
7%
Targeted Therapy
7%
Survival Benefit
7%
Kaplan-Meier Method
7%
Retrospective Analysis
7%
Phase III Clinical Trial
7%
Metastatic Disease
7%
Survival Outcomes
7%
Phase II Clinical Trial
7%
Multivariate Cox Regression Analysis
7%
Tumorigenic Effects
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non-Steroidal Anti-Inflammatory Drug
100%
Kidney Metastasis
100%
Acetylsalicylic Acid
100%
Progression Free Survival
28%
Overall Survival
28%
Clinical Trial
7%
Adverse Event
7%
Renal Cell Carcinoma
7%
Carcinogenesis
7%
Metastasis
7%
Immunology and Microbiology
Carcinoma Cell
100%
Overall Survival
100%
Progression Free Survival
100%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Progression Free Survival
100%
Clinical Trial
25%
Carcinogenesis
25%